Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases

Abstract

The invention relates to the use of a chemical substance selected from the group consisting of N-'2-hydroxy-3-(1piperidinyl)-propoxy]-1-pyridine-1-oxide-3-carboximidoyl chloride, the optically active enantiomers and the mixtures of enantiomers thereof and pharmaceutically acceptable salts of the racemic and optically active compounds in the preparation of a pharmaceutical composition for the treatment or prevention of neurodegenerative diseases.

1 . A method of treating a patient with a neurodegenerative disease of the central nervous system, said method comprising administering a therapeutically effective amount of (+)-R-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride citrate to said patient. 
     
     
         2 . The method according to  claim 1 , wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, central nervous system neuropathies and amyotrophic lateral sclerosis. 
     
     
         3 . The method according to  claim 1 , wherein said (+)-R-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride citrate is administered to said patient at a daily dose of 0.1-400 mg/kg. 
     
     
         4 . The method according to  claim 1 , wherein said (+)-R-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride citrate is administered to said patient at a daily dose of 0.1-100 mg/kg. 
     
     
         5 . The method according to  claim 1 , wherein said (+)-R-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride citrate is administered to said patient at an oral daily dose of 10-300 mg.